Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maxxim Medical

This article was originally published in The Gray Sheet

Executive Summary

Extends to Nov. 10 the expiration of its offer to purchase for cash any and all of the $100 mil. aggregate principal amount of its outstanding 10-1/2% senior subordinated notes due 2006. Holders of over $99.9 mil. of the notes had tendered their notes and delivered consents to amendments prior to the consent expiration date. Previously scheduled to expire on Oct. 29, the tender offer was launched in connection with Maxxim's previously announced proposal to merge with Fox Paine Medic Acquisition Corporation and recapitalize the company (1"The Gray Sheet" June 21, p. 19). The merger is expected to close in "mid-November," Maxxim says

You may also be interested in...



Maxxim Medical Management-Led Leveraged Buyout Valued At $800 Mil.

The management of Maxxim Medical plans to take the specialty medical products company private with the help of Foster City, California-based investment firm Fox Paine & Company and Chase Manhattan.

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

UsernamePublicRestriction

Register

SC143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel